Chemomab Therapeutics (CMMB) reported that it has obtained confirmation from the FDA on two significant development milestones as the company continues to finalize the nebokitug Phase 3 program. As part of the FDA End-of-Phase 2, EOP2, review process, Chemomab and the FDA addressed multiple Chemistry, Manufacturing, and Controls, CMC, topics critical to ensuring the quality and consistency of drug supply for the late-stage development and eventual commercialization of nebokitug. Following productive discussions, the FDA indicated agreement with the CMC strategy proposed by Chemomab and its contract manufacturing partner.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Chemomab announces nebokitug awarded new patent protection in China, Russia
- Chemomab Therapeutics Announces Annual General Meeting for July 2025
- Chemomab Therapeutics: Promising Prospects with Streamlined Path to Approval and Strategic Advancements
- Chemomab Therapeutics Advances Nebokitug for PSC Treatment
- Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer